AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra’s obesity drug. AI takes center stage at HIMSS ...

OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel ...

StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research note issued to investors on Monday morning. The brokerage issued a hold rating on the ...

Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million ––Q4 Total Revenue Grew 114% ...

Reports Q4 revenue $69.1M, consensus $61.58M. “The significant progress we and our partners achieved throughout 2024 has formed a strong ...

Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.

The "Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.The "Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2025" report ...

Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ETCompany ParticipantsCourtney Dugan - Head-IRMichael Rossi ...

Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

DNA repair proteins act like the body's editors, constantly finding and reversing damage to our genetic code. Researchers have long struggled to understand how cancer cells hijack one of these ...

Mural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc , a global healthcare intelligence and clinical research organization, today announce a partnership to ...

We reduced our fair value estimate to $15.50 per share from $27.20 to account for greater headwinds as a newly stand-alone company since its spinoff from Labcorp in 2023, which will weigh on revenue ...